Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ analysis
B-Lymphocytes
/ immunology
Betacoronavirus
/ immunology
COVID-19
Child
Cohort Studies
Coronavirus Infections
/ immunology
Female
Humans
Immunoassay
/ methods
Immunoglobulin G
/ analysis
Immunoglobulin M
/ analysis
Lymphocyte Subsets
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ immunology
SARS-CoV-2
T-Lymphocytes
/ immunology
Young Adult
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
28
7
2020
medline:
29
9
2020
entrez:
26
7
2020
Statut:
ppublish
Résumé
Without a specific antiviral treatment or vaccine, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, affecting over 200 countries worldwide. A better understanding of B- and T-cell immunity is critical to the diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19). A cohort of 129 patients with COVID-19 and 20 suspected cases were enrolled in this study, and a lateral flow immunochromatographic assay (LFIA) and a magnetic chemiluminescence enzyme immunoassay (MCLIA) were evaluated for SARS-CoV-2 IgM/IgG detection. Additionally, 127 patients with COVID-19 were selected for the detection of IgM and IgG antibodies to SARS-CoV-2 to evaluate B-cell immunity, and peripheral blood lymphocyte subsets were quantified in 95 patients with COVID-19 to evaluate T-cell immunity. The sensitivity and specificity of LFIA-IgM/IgG and MCLIA-IgM/IgG assays for detecting SARS-CoV infection were > 90%, comparable with reverse transcription polymerase chain reaction detection. IgM antibody levels peaked on day 13 and began to fall on day 21, while IgG antibody levels peaked on day 17 and were maintained until tracking ended. Lymphocyte and subset enumeration suggested that lymphocytopenia occurred in patients with COVID-19. LFIA-IgM/IgG and MCLIA-IgM/IgG assays can indicate SARS-CoV-2 infection, which elicits an antibody response. Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response.
Sections du résumé
BACKGROUND AND OBJECTIVE
Without a specific antiviral treatment or vaccine, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic, affecting over 200 countries worldwide. A better understanding of B- and T-cell immunity is critical to the diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19).
METHODS
A cohort of 129 patients with COVID-19 and 20 suspected cases were enrolled in this study, and a lateral flow immunochromatographic assay (LFIA) and a magnetic chemiluminescence enzyme immunoassay (MCLIA) were evaluated for SARS-CoV-2 IgM/IgG detection. Additionally, 127 patients with COVID-19 were selected for the detection of IgM and IgG antibodies to SARS-CoV-2 to evaluate B-cell immunity, and peripheral blood lymphocyte subsets were quantified in 95 patients with COVID-19 to evaluate T-cell immunity.
RESULTS
The sensitivity and specificity of LFIA-IgM/IgG and MCLIA-IgM/IgG assays for detecting SARS-CoV infection were > 90%, comparable with reverse transcription polymerase chain reaction detection. IgM antibody levels peaked on day 13 and began to fall on day 21, while IgG antibody levels peaked on day 17 and were maintained until tracking ended. Lymphocyte and subset enumeration suggested that lymphocytopenia occurred in patients with COVID-19.
CONCLUSIONS
LFIA-IgM/IgG and MCLIA-IgM/IgG assays can indicate SARS-CoV-2 infection, which elicits an antibody response. Lymphocytopenia occurs in patients with COVID-19, which possibly weakens the T-cell response.
Identifiants
pubmed: 32710269
doi: 10.1007/s40291-020-00486-3
pii: 10.1007/s40291-020-00486-3
pmc: PMC7380500
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-609Subventions
Organisme : National Natural Science Foundation of China
ID : 81773394
Pays : International
Références
Rev Med Virol. 2020 May;30(3):e2106
pubmed: 32302058
Pathogens. 2019 Sep 11;8(3):
pubmed: 31514485
Curr Med Chem. 2011;18(21):3226-33
pubmed: 21671854
J Immunol Res. 2019 Feb 18;2019:1386740
pubmed: 30906787
J Exp Med. 2007 Mar 19;204(3):645-55
pubmed: 17312005
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
J Clin Lab Anal. 2020 Sep;34(9):e23411
pubmed: 32594577
Radiology. 2020 Aug;296(2):E41-E45
pubmed: 32049601
Emerg Infect Dis. 2007 Oct;13(10):1562-4
pubmed: 18258008
Hong Kong Med J. 2016 Jun;22(3 Suppl 4):25-31
pubmed: 27390007
Respirology. 2006 Jan;11(1):49-53
pubmed: 16423201
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Mar 30;40(3):316-320
pubmed: 32376571
J Cancer Res Ther. 2018 Jun;14(Supplement):S331-S335
pubmed: 29970685
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
J Microbiol Immunol Infect. 2020 Oct;53(5):705-714
pubmed: 30914258
Virol J. 2014 May 06;11:82
pubmed: 24885320
Allergy. 2020 Jul;75(7):1564-1581
pubmed: 32396996
Immunol Lett. 2007 Jan 15;108(1):45-51
pubmed: 17129612
Int J Infect Dis. 2017 May;58:45-51
pubmed: 28249810
Immunity. 2018 Feb 20;48(2):202-213
pubmed: 29466753
Tunis Med. 2019 Feb;97(2):327-334
pubmed: 31539091
Pediatr Int. 2019 Jan;61(1):16-22
pubmed: 30248214
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Feb 29;40(2):164-167
pubmed: 32376546
J Infect. 2020 Jul;81(1):e28-e32
pubmed: 32283141